Entia non sunt multiplicanda praeter necessitate.
William of Ockham (c. 1285-1349), author of the Ockham’s Razor principle.
CLINICAL TRIALS
Phase IIa trials in patients with CF and NCFBE
Ockham, together with the support of Life Arc (see News are currently developing a proprietary formulation of heparin (OCK4), in a bespoke hand-held nebuliser for pulmonary administration in the treatment of cystic fibrosis (CF) and non-CF bronchiectasis (NCFBE). The immediate objective is to undertake Phase IIa trials in patients with CF and NCFBE.
Preparatory work to set up the trials and obtain regulatory clearance is underway, with studies due to begin in 2025.